- Companies
- Wayspring
Wayspring Funding, Investors & Competitors
Wayspring has raised $161M across 6 funding rounds, most recently a $45M Series D in May 2024.
Last Wayspring funding round
$45M
Series D · May 2024
Cumulative funding Wayspring raised
$161M
across 6 funding rounds
Key investors in Wayspring
.406 Ventures
The Blue Venture Fund
Sandbox Industries
Oak HC/FT
HLM Venture Partners
Valtruis
CVS Health Ventures
Centene
About Wayspring
Wayspring is a Boston-based value-based healthcare provider delivering medical, behavioral health, and social services to individuals with complex needs, particularly those with substance use disorders. The organization employs a longitudinal care model featuring member outreach, peer support networks, and provider collaborations to boost evidence-based treatment adherence and health outcomes while reducing costs. Wayspring serves members in multiple states through integrated primary care and recovery programs.
Founded
2012
HQ
Website
Status
Privately held
Customer focus
B2C
Revenue model
Services
Wayspring Funding History
Wayspring has raised a total of $161M across 6 funding rounds.
Wayspring's first fundraising round was a $2M Series A in September 2014. The most recent completed round was a $45M Series D in May 2024.
Wayspring funding rounds
| Date | Stage | Investors | Raised | Deal Summary |
|---|---|---|---|---|
| May 2024 | Series D | CVS Health Ventures (lead); .406 Ventures; HLM Venture Partners; Valtruis | $45M | Wayspring, a Nashville-based value-based care company specializing in substance use disorder (SUD) populations, secured a $45 million minority investment on May 21, 2024, led by CVS Health Ventures with participation from existing investors Valtruis, HLM Venture Partners, and .406 Ventures. The funding aims to expand Wayspring's SUD Home Program, which integrates clinical care with social determinants of health for accessible, patient-centered treatment to improve outcomes and reduce costs. Wayspring partners with health plans across eight states and plans to enter two new states in 2024. The investment highlights Wayspring's success in executing a complex care model for SUD patients, as noted by CVS Health Ventures' Justin Brock, who praised early results and potential collaboration. CEO Carter Paine emphasized the support's role in scaling compassionate care strategies to transform SUD treatment delivery. CVS Health Ventures focuses on early- and growth-stage companies enhancing healthcare accessibility, affordability, and simplicity through care delivery transformation and whole-person care. |
| Sep 2021 | Series D | Valtruis (lead); The Blue Venture Fund; .406 Ventures; HLM Venture Partners; Highmark Ventures; CareSource Foundation; Oak HC/FT; Centene | $75M | Wayspring, formerly axialHealthcare, is a Nashville-based startup providing a value-based care solution through a full-risk medical home model for substance use disorder (SUD) treatment. The platform helps healthcare providers manage patients' risk of addiction to pain medication by flagging risk factors and supporting navigation to appropriate treatment. On September 28, 2021, Wayspring announced a $75 million funding round led by Valtruis, the value-based care portfolio company of Welsh, Carson, Anderson & Stowe, with participation from Centene Corporation, CareSource, and HLM Venture Partners. Existing investors including Highmark Ventures, .406 Ventures, The Blue Venture Fund, and Oak HC/FT also contributed, bringing total funding to about $100 million following prior rounds of $1.75 million and $8 million series A. The investment aims to scale Wayspring's SUD treatment model, addressing complex challenges in addiction care amid growing healthcare needs. CEO Carter Paine highlighted the strong track record of Valtruis in scaling transformational healthcare companies. Valtruis Managing Director Karey Witty noted this as the second partnership with WCAS to build value-based platforms for pervasive issues, following Cricket Health in kidney care. No financial metrics such as post-money valuation, revenue, ARR, EBITDA, or valuation multiples were disclosed in the funding announcements across multiple sources including press releases and industry news. |
| Feb 2020 | Series C | Oak HC/FT (lead); The Blue Venture Fund; .406 Ventures; Sandbox Industries | $15M | - |
| Oct 2016 | Series B | Oak HC/FT (lead); The Blue Venture Fund; .406 Ventures; Sandbox Industries | $17M | Wayspring (formerly AxialHealthcare) raised $16.5 million in a Series B funding round in October 2016 led by Oak HC/FT, with participation from .406 Ventures and the Blue Venture Fund. The company operates a value-based care platform for substance use disorder treatment that helps healthcare providers manage patient addiction risk to pain medication. |
| Jul 2015 | Series A | .406 Ventures (lead); The Blue Venture Fund; Sandbox Industries | $8M | Wayspring, previously known as AxialHealthcare, is a US-based provider of addiction management services that helps healthcare providers manage patients’ risk of addiction to pain medication by flagging risk factors and potential substance use disorders. The company operates a value-based care solution featuring a full-risk medical home model that includes community-based peer support, behavioral health services, primary care, and partnerships with provider networks to direct members to high-quality treatment and manage care transitions. In July 2015, Wayspring closed an $8 million Series A funding round led by .406 Ventures, with participation from Sandbox Industries and The Blue Venture Fund. This followed a $1.75 million seed round the prior year co-led by The Blue Venture Fund and Sandbox Industries. The Series A built on early momentum in addressing substance use disorder challenges. Subsequent rounds included a $16.5 million Series B in 2016 and a $15 million Series C in February 2020, both backed by .406 Ventures, The Blue Venture Fund, and Sandbox Industries, alongside Oak HC/FT. Wayspring continued raising capital, including a $75 million round in 2021 led by Valtruis with Centene, CareSource, and others, and later investments like one led by CVS Health Ventures in 2024. |
| Sep 2014 | Series A | Sandbox Industries (lead); The Blue Venture Fund (lead) | $2M | - |
Who has invested in Wayspring?
10 investors have backed Wayspring across its funding rounds, including .406 Ventures, The Blue Venture Fund, Sandbox Industries, Oak HC/FT, HLM Venture Partners and Valtruis.
Lead investors include CVS Health Ventures, Valtruis, Oak HC/FT, .406 Ventures, Sandbox Industries and 1 other investor.
Wayspring Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| 5 | Lead | Sep 2014 | ||
| 5 | Lead | Jul 2015 | ||
| 4 | Lead | Sep 2014 | ||
| 3 | Lead | Oct 2016 | ||
| 2 | Participant | Sep 2021 | ||
| 2 | Lead | Sep 2021 | ||
| 1 | Participant | Sep 2021 | ||
| 1 | Participant | Sep 2021 | ||
This data is available for Pro users. Sign up to see all 10 Wayspring investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialWayspring Competitors
Wayspring competitors include listed companies like UnitedHealth Group and Molina Healthcare, and private ones like Devoted Health, WeDoctor, Cityblock Health and Grand Rounds.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Private | $3.3B | - | $13B | 4.0x | ||
| Private | $139M | - | $7B | 50.4x | ||
| Private | - | - | $5.7B | - | ||
| Private | - | - | $1.3B | - | ||
| Publicly listed | $448B | $23B | $337B | 0.9x | ||
| Publicly listed | $45B | $976M | $11B | 0.1x |
Wayspring Public Comps
Wayspring is still privately-owned, but its public comps include UnitedHealth Group, Molina Healthcare, Max Healthcare Institute, Oscar Health, Fortis Healthcare, Hims, Clover Health, Alignment Healthcare, Ping An Healthcare and JMDC.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $448B | $23B | 0.9x | 0.9x | 16.7x | 13.3x | |||
| $45B | $976M | 0.1x | 0.1x | 5.9x | 7.2x | |||
| $858M | $232M | 12.6x | 10.2x | 46.5x | 36.8x | |||
| $12B | ($391M) | 0.5x | 0.4x | (15.9x) | 12.8x | |||
| $943M | $215M | 7.8x | 7.1x | 34.1x | 31.0x | |||
| $2.3B | $178M | 3.1x | 2.4x | 40.4x | 23.9x | |||
| $1.9B | ($84M) | 1.1x | 0.8x | (25.8x) | 34.1x | |||
| $3.9B | $45M | 0.4x | 0.3x | 31.6x | 10.0x | |||
This data is available for Pro users. Sign up to see all Wayspring competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Wayspring
| When was Wayspring founded? | Wayspring was founded in 2012. |
| Where is Wayspring headquartered? | Wayspring is headquartered in Nashville, TN, United States. |
| Is Wayspring publicly listed? | No, Wayspring is a private, VC-backed company. |
| How much funding has Wayspring raised? | Wayspring has raised $161M across 6 funding rounds. |
| What was Wayspring's last funding round? | Wayspring's last funding round was a $45M Series D in May 2024, led by CVS Health Ventures. |
| Who are Wayspring's investors? | Wayspring's investors include The Blue Venture Fund, .406 Ventures, Sandbox Industries, Oak HC/FT, HLM Venture Partners, Valtruis, Highmark Ventures, CareSource Foundation, CVS Health Ventures and Centene. |
| Which companies are comparable to Wayspring? | Companies comparable to Wayspring include Devoted Health, WeDoctor, Cityblock Health, Grand Rounds, UnitedHealth Group and Molina Healthcare. |
See companies similar to Wayspring
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




